Vibe Bio Newsletter — April 2025
Every Cure for Every Community — The Role of AI in Drug Development Decision-Making
Thanks for reading Vibe Bio’s Monthly Newsletter! Stay up-to-date with insights into the biotech landscape and the latest from our team in our pursuit of every cure for every community.
Industry updates & resources
Fierce Pharma | Pfizer, in sweeping cost cutting push, lifts overall savings target to $7.7B
Vibe Bio | How to improve biopharma business development with AI-powered due diligence
BioPharma Dive | FDA misses approval deadline for biotech’s rare disease drug
Fierce Biotech | Roche receives FDA breakthrough label for AI-powered lung cancer companion diagnostic test
Vibe Bio | Biopharma BD&L: the tsunami is upon us
Fierce Biotech | GSK takes advantage of natural experiment to study whether shingles vaccine can reduce dementia risk
BusinessWire | Orphan Therapeutics Accelerator Announces Foundational Partnerships
Fierce Biotech | Eli Lilly pens Creyon Bio AI oligonucleotide pact with $1B in biobucks on the table | Fierce Biotech
PR Newswire | Granata Bio Expands Women's Health Portfolio with Acquisition of US-Based Oviva Therapeutics
Monthly rewind
Challenges in business development
In biopharma business development, many companies are trying to find the next blockbuster drug, but lack the necessary resources to make informed decisions quickly.
In this process, a set of common challenges emerge for BD teams dedicated to finding the assets that best fit their needs, including:
Limited resources and time constraints: BD activities require considerable time and effort to evaluate potential programs and identify the most promising ones for their business.
Proliferation of new mechanisms, modalities, and technologies as it’s applied to therapeutics.
Intense competition necessitates quick decision-making: Biopharmas need to combat loss of exclusivity and compete with new biopharma companies to fill pipeline gaps.
Complexity of evaluating diverse scientific data from a variety of sources, written in different languages and delivered in different formats.
AI has the potential to change the biopharma BD landscape, providing an important way to keep up in an increasingly competitive and data-driven industry.
Read this blog post to learn more about how AI can help overcome due diligence challenges.
Competitive landscape analysis:
As pharma companies seek to identify the right partners with AI-powered solutions to improve competitive landscape analysis, the focus is on finding solutions that have proven their ability to deliver on those promises.
Here are the capabilities to look for in an AI-powered solution:
Make portfolio decisions: Get the information you need about existing approved drugs, drugs in development, and potential competitors. AI-powered competitive landscape analysis helps you make data-driven decisions about which drug or area to focus on.
Explore a therapeutic area: AI-powered program analysis can show you a “stacked” landscape that details competitors across multiple indications within that area, so it’s easy to understand what’s already approved, what’s on the horizon, and what gaps still exist.
Make decisions at scale: Tracking and managing dozens or hundreds of competitive drugs is incredibly difficult. An AI-powered pipeline analysis platform makes it simpler by collecting structured and unstructured data, normalizing it, and making it all queryable. A visualization of that data makes analysis easier, even in large, crowded therapeutic areas.
Ask questions: AI-analysis makes it simple to pinpoint underserved indications, understand competitor timelines, and position yourself strategically against upcoming competition.
If you’re interested in learning how to optimize your competitive landscape analysis, Vibe Bio is here to support your pipeline analysis and portfolio analysis goals. Learn how we can help.
What we’re hearing:
As Vibe Bio continues to grow and build out the capabilities of its AI-powered pipeline and program analysis platform, we speak with many organizations operating in the biopharma space. One recent call was with a medical school focused on early-stage assets and intellectual property from university research. During the call, the team shared some of their pain points and needs:
We have a slow, manual process for asset evaluation and comparison
We need better ways to:
Assess early-stage assets (primarily preclinical)
Compare assets against the existing landscape
Position assets for partners/investors
Determine competitive advantages
Guide investment decisions
Our current workflow involves three levels:
IP investment decisions
Internal positioning/campaign planning
External non-confidential pitch decks
We need to be able to compare internal assets and update outputs based on new data quickly
As we talked through these pain points and needs, the potential value of AI analysis is clear. For this university, conducting preclinical analysis, evaluating early stage assets, and establishing their position would help their team move faster and with greater confidence.
What’s coming soon
Coming up June 16-19, we’ll be at the BIO 2025, an international convention representing the full biotech ecosystem. BIO brings together 20,000 industry leaders from around the world to help people make connections and build relationships in biotechnology. See you in Boston this June!
Stay tuned for how to connect with the Vibe Bio team at the event — and if you’re not already registered, here’s the registration link for the BIO International Convention.
Inside the Vibe Bio team
If you’ve read our newsletter before, you already know we use Discord to stay connected, but we also gather together in real life! Earlier this month, most of us met up in Boston for some team bonding, product and project planning, and to catch up with one of our portfolio companies, Granata Bio.
Meet the team! Top row from left to right: Kristen Schultz, Sean Ho, Andy Birch, Herbert Hall, Matt Kramer, and Christina Wong
Bottom row from left to right: Alok Tayi, PhD, Remie Yu, Michelle Deery, and Haidee LeClair
Learn more about us on our website!
Listening to every community
Community building is a top priority for us! Learn about how we're driving our mission to find every cure for every disease and join the conversation! Follow us on social media to stay up-to-date with the latest news and updates from our community.
Tell us what else you’d like to see in future editions of the newsletter. We’d love to hear from you!
Sincerely,
The Vibe Bio Team
#EveryCureforEveryCommunity